These Four Emerging Companies Deserve a Look

Jun 20, 2016, 11:34 ET from FN Media Group, LLC

MIAMI, June 20, 2016 /PRNewswire/ -- Briefing: LifeClips Inc. (OTC: LCLP) (OTCQB: LCLP) has been gaining a lot of attention over the weekend following several reports from social financial sites like Investors Hub, that the company's newly acquired company, Batterfly Energy, has its Mobeego product already placed in high profile outlets like in the US like the MGM Grand Hotel's "Grand & Co." (

This morning the company announced that it has secured distribution in 400 B&M discount retail stores throughout the UK, via its UK Distributor Mobeego Scotland ltd. "B&M is one of the fastest growing discount retail chains in the UK. All of us at LifeClips are very excited about this new deal with B&M. This is all part of our continuing and successful effort to expand and grow LifeClips.  I believe that the amount of exposure & potential revenue that comes from being in 400 retail locations of a brand of stores like B&M which has 3 million customer transactions per week could be huge!" said Bob Gruder CEO of LifeClips, Inc.

Since opening the day the stock has begun to test higher levels at $0.59 and $0.60.  Within the last month the stock has seen highs over $0.70

Lpath Inc. (NASDAQ: LPTN) has taken off this morning after announcing that the company has been awarded a $1.45 million two-year grant by the Defense Medical Research and Development Program, an agency of the U.S. Department of Defense.  According to the company, this DoD grant will fund preclinical studies designed to evaluate the ability of Lpathomab to alleviate pain following neurotrauma, and to confirm the potential efficacy of Lpathomab as previously demonstrated by Stanford University researchers in an animal model of TBI pain.

 LPTN is the category leader in lipid-targeted therapeutics. The company's ImmuneY2™ drug-discovery engine has the unique ability to generate therapeutic antibodies that bind and inhibit bioactive lipids that contribute to disease.

Since closing last Friday afternoon, June 17, at $2.08, shares of LPTN have exploded in price to as highs as $4.09 in early morning trading on Monday.  This 97% increase in price has attracted a lot of attention and has put LPTN as one of the most actively traded small cap stocks trading on the NASDAQ

Macrocure, Inc. (NASDAQ: MCUR) has also seen above average trading activity on Monday.  After closing out last week at a price of $1.27 the stock has increased to highs of $1.70 in early morning trading.  Though there isn't a whole lot of recent news coverage or guidance from the company, the last announcement made in April of this year explained that the company is a clinical-stage biotechnology company that until recently was focused on developing a novel therapeutic platform to address chronic and hard-to-heal wounds.

MCUR's lead product candidate, CureXcell®, is a combination of living human white blood cells that have been activated to allow for the healing process and stimulate wound closure. According to the company, CureXcell® addresses each phase of healing in the impaired wound, including the production of growth factors and other biochemical factors involved in fibroblast activation, cell migration and extracellular matrix production, stimulating the body's natural healing process. 

Neovasc Inc. (NASDAQ: NVCN) has been one of the more active stocks in the market over the last 2 days.  This morning the company announced that they had recorded positive results of a single center, retrospective study using the Reducer.  According to Neovasc, the paper documented the results from 23 straight patients who were implanted with the Reducer to treat their severe refractory angina. Results showed that in "all 23 patients, the Reducer device was implanted in a day hospital successfully setting without any adverse events."

"Despite the large range of available anti-ischaemic medical therapies and revascularization techniques, a considerable number of patients still suffer from angina which is refractory to medical treatment," said Dr. Pierfrancesco Agostoni, Interventional Cardiologist and senior author of the study. 

Since Friday June 17, shares of NVCN have increase from $0.52 to as high as $1.28 on Monday morning.  This has been a near 150% move in just a few days as trading volume has continued to remain well above average in comparison to previous weeks of trading in the stock.  

DISCLAIMER: is Source of all content listed above.  FN Media Group, LLC (FNM), is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNM is NOT affiliated in any manner with or any company mentioned herein.  The commentary, views and opinions expressed in this release by are solely those of and are not shared by and do not reflect in any manner the views or opinions of FNM.  The companies that are discussed herein may or may not have approved the statements made in this release.  FNM is not liable for any investment decisions by its readers or subscribers.  FNM and its affiliated companies are a news dissemination and financial marketing solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security.  FNM was not compensated by any public company mentioned herein to disseminate this press release.


This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNM undertakes no obligation to update such statements.

Contact Information: Company: FN Media Group, LLC Contact e-mail: U.S. Phone: +1(954)345-0611 URL:

SOURCE FN Media Group, LLC